Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIA 9-1067 in Parkinson's disease with wearing-off
2010-021860-13Phase 3Completed
- Sponsor
- BIAL
- Start
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of opicapone in Parkinson's disease (PD) (5 arms), sponsored by BIAL. Primary endpoint: Primary efficacy endpoint. Started Sep 2010; status: completed.
02
Drugs
opicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2010-021860-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021860-13.